Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia.
Reverse translated and gold standard continuous performance tests predict global cognitive performance in schizophrenia.
复制标题
DOI:
10.1038/s41398-018-0127-5
复制
发表时间:
2018-04-12
影响因子:
6.8
通讯作者:
Light GA
中科院分区:
文献类型:
--
作者:
Bismark AW;Thomas ML;Tarasenko M;Shiluk AL;Rackelmann SY;Young JW;Light GA
Attentional dysfunction contributes to functional impairments in schizophrenia (SZ). Sustained attention is typically assessed via continuous performance tasks (CPTs), though many CPTs have limited cross-species translational validity and place demands on additional cognitive domains. A reverse-translated 5-Choice Continuous Performance Task (5C-CPT) for human testing—originally developed for use in rodents—was designed to minimize demands on perceptual, visual learning, processing speed, or working memory functions. To-date, no studies have validated the 5C-CPT against gold standard attentional measures nor evaluated how 5C-CPT scores relate to cognition in SZ. Here we examined the relationship between the 5C-CPT and the CPT-Identical Pairs (CPT-IP), an established and psychometrically robust measure of vigilance from the MATRICS Consensus Cognitive Battery (MCCB) in a sample of SZ patients (n = 35). Relationships to global and individual subdomains of cognition were also assessed. 5C-CPT and CPT-IP measures of performance (d-prime) were strongly correlated (r = 0.60). In a regression model, the 5C-CPT and CPT-IP collectively accounted for 54% of the total variance in MCCB total scores, and 27.6% of overall cognitive variance was shared between the 5C-CPT and CPT-IP. These results indicate that the reverse translated 5C-CPT and the gold standard CPT-IP index a common attentional construct that also significantly overlaps with variance in general cognitive performance. The use of simple, cross-species validated behavioral indices of attentional/cognitive functioning such as the 5C-CPT could accelerate the development of novel generalized pro-cognitive therapeutics for SZ and related neuropsychiatric disorders.
登录
查看更多内容
影响因子:
4.5
作者:
Bismark AW;Thomas ML;Tarasenko M;Shiluk AL;Rackelmann SY;Young JW;Light GA
通讯作者:
Light GA
影响因子:
11.3
作者:
Lee, Kwang-Hyuk;Tsoi, Daniel T.;Woodruff, Peter W. R.
通讯作者:
Woodruff, Peter W. R.
DOI:
10.1111/gbb.12268
发表时间:
2016-01
期刊:
Genes, brain, and behavior
影响因子:
--
作者:
Cope ZA;Powell SB;Young JW
通讯作者:
Young JW
DOI:
10.1176/appi.ajp.2017.16040400
发表时间:
2017-07-01
期刊:
The American journal of psychiatry
影响因子:
--
作者:
McTeague LM;Huemer J;Carreon DM;Jiang Y;Eickhoff SB;Etkin A
通讯作者:
Etkin A
影响因子:
3.4
作者:
Barnes SA;Young JW;Neill JC
通讯作者:
Neill JC